Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company. Just over a year ago ...

Moving on to Sepranolone. On February 6th, we acquired Sepranolone as a potential therapy for Tourette syndrome and other compulsion related condition from Asarina Pharma. We believe that ...

In other recent news, Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB for approximately 3 million EUR. This compound is ...

In other recent news, Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB for approximately 3 million EUR. This compound is being ...

As of December 31 the Company had cash, cash equivalents, and short-term investments of approximately $44.9M, compared to cash, cash ...

Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.

UK-based Trimtech Therapeutics, a biotech harnessing targeted protein degradation (TPD) for neurodegenerative diseases, has announced the closing of its $31 million seed funding round. The investment ...